Pipeline & Proof of Concept

Our robust and growing pipeline has the potential to play a critically influential role in the practice of Gut Microbiome Medicine and create significant value for patients and shareholders.

Dr. Eugene Chang’s NIH-funded lab, the Chang Lab at the University of Chicago in collaboration with The University of Chicago Duchossois Family Institute produced the GB diagnostic technology platform.

Therapeutic area

Gut Microbiome

Functional Health

GI Disease Management

Indication

POC*

DISCOVERY & IDEATION

INVENTION & PROTOTYPING

PRECLINICAL

CLINICAL

Regulatory Decision

Adults (ages 18-64)

Early Childhood Development (0-5)

Older Adult Longevity (ages 65+)

GB-0001

GB-00XX

GB-00XX

Irritable Bowel Syndrome (IBS)

IBD Patients Mangement /
Biological Therapy

C. diff (Clostridioides difficile)

GB-0001

GB-00XX

GB-00XX

Unmet need and thought leadership:

CS Therapeutic Platform Technology Pipeline:

Therapeutic area

Infectious Diseases

Oncology

Indication

POC*

DISCOVERY

PRECLINICAL

Phase I

Phase II

Phase III

Surgical Site Infection

Sepsis

Wound Site Virulence Suppression

CS-0003

CS-0003

CS-00XX

Colon Cancer Recurrence

Chemotherapy Related Toxicities
and Infections

CS-00XX

CS-00XX

The study is in progress.

Highlighted Proof of Concept Publications Below:

Anastomotic Leak

SSI via Trojan Horse Mechanism

Sepsis

Colon Cancer Recurrence

Thought Leadership